Compare Celsius Holdings, Inc. (CELH) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Celsius Holdings, Inc. trades at $27.6 (market cap $7.11B), while IDEXX Laboratories, Inc. trades at $571.52 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.5× Celsius Holdings, Inc.'s market cap. Which is the better fit depends on your goals.
| CELH | IDXX | |
|---|---|---|
Market Cap | $7.11B | $46.22B |
Sector | Consumer Staples | Health |
52-Week High | $64.86 | $766.68 |
52-Week Low | $23.77 | $526.44 |
Enterprise Value | $8.90B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CELH trades at $27.37, up 0.59% on the day, but its technical outlook is bearish with key support at $26. Revenue growth remains strong, reaching $2.52B in 2025, though net income margins have compressed to 4.24%. The company faces headwinds from a recent earnings miss and core brand weakness, but maintains a robust 95.65% analyst buy rating with a $44.08 consensus price target.
The stock offers significant upside potential based on analyst targets, but risks include execution challenges, intense competition, and margin pressure. Investor sentiment is cautious due to slowing growth and leadership changes, yet the long-term growth story, supported by the PepsiCo partnership, remains intact for patient investors.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
